• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor
    Hero Background

    South Korea Ophthalmic Drugs Devices Market

    ID: MRFR/Pharma/51779-HCR
    200 Pages
    Garvit Vyas
    October 2025

    South Korea Ophthalmic Drugs and Devices Market Research Report By Product (Drugs, Devices) and By Treatment (Eye Infections, Allergic Conjunctivitis, Dry Eyes Syndrome, Red Eyes, Inflammation, Others)- Forecast to 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    South Korea Ophthalmic Drugs Devices Market Infographic
    Purchase Options

    South Korea Ophthalmic Drugs Devices Market Summary

    The South Korea Ophthalmic Drugs and Devices market is poised for substantial growth, projected to reach 7.2 USD Billion by 2035.

    Key Market Trends & Highlights

    South Korea Ophthalmic Drugs and Devices Key Trends and Highlights

    • The market valuation is expected to increase from 1.25 USD Billion in 2024 to 7.2 USD Billion by 2035.
    • A compound annual growth rate (CAGR) of 17.25% is anticipated from 2025 to 2035.
    • The increasing prevalence of eye disorders is likely to drive demand for ophthalmic drugs and devices in South Korea.
    • Growing adoption of advanced diagnostic technologies due to rising awareness of eye health is a major market driver.

    Market Size & Forecast

    2024 Market Size 1.25 (USD Billion)
    2035 Market Size 7.2 (USD Billion)
    CAGR (2025-2035) 17.25%

    Major Players

    Amgen, Sun Pharmaceutical, Alcon, Merck, Ocular Therapeutix, Johnson & Johnson, Glaukos, MediEye, Bausch Health, Aerie Pharmaceuticals, AbbVie, Hugel, Novartis, Santen Pharmaceutical

    South Korea Ophthalmic Drugs Devices Market Trends

    The South Korea Ophthalmic Drugs and Devices Market is showing significant shifts as a result of an older demographic and the growing occurrence of eye-related illnesses. The government is aware of improving healthcare services and is, therefore, promoting the development of ophthalmic care and technology.

    There is an upsurge of research initiatives focusing on creating new drugs and devices suitable for the South Korean population which addresses their specific needs. Furthermore, the growth of digital health and telemedicine innovations are transforming eye care services in ophthalmology by offering patients easier access to consultations and greatly enhancing the accessibility of eye care.

    The expansion of opportunities in the ophthalmic sector in South Korea is fueled by local firms looking to partner with foreigners for easier transfer of knowledge and quicker innovation. Companies are now actively investing in advanced technologies because there is a high demand for sophisticated diagnostic devices and surgical instruments.

    With the new policies of the South Korean government aiming to increase the level of healthcare concerning chronic eye diseases, new product lines specific to glaucoma treatment and retinal care are set to emerge. More focal attention is given to personalized medicine in ophthalmology, and the care patients receive is shifting to more individualized treatment plans.

    Moreover, their expansion comes with the help of South Korean e-commerce. The shift in purchasing patterns of patients looking for ophthalmic medicines towards online pharmacies shows that traditional pharmacies need to rethink their business approach. All of these changes show that there is strong technological growth and innovative shifts occurring that are actively working to satisfy the needs of the citizens of South Korea.

    Market Segment Insights

    Ophthalmic Drugs and Devices Market Product Insights

    The South Korea Ophthalmic Drugs and Devices Market is characterized by a diverse array of products that cater to various ocular conditions, underscoring the increasing awareness and focus on eye health in the region. With the national emphasis on improving healthcare access and quality, the market has witnessed a significant shift towards innovative ophthalmic solutions.

    The product segment can be broadly divided into drugs and devices, each playing a crucial role in addressing eye diseases. Drugs, including anti-inflammatories, glaucoma medications, and anti-VEGF therapies, are essential for managing both chronic and acute ophthalmic conditions, thereby promoting patient compliance and enhancing treatment outcomes.

    Meanwhile, devices such as diagnostic equipment and surgical instruments are vital in the detection, monitoring, and intervention of ocular disorders. The growing prevalence of vision-related issues, including age-related macular degeneration and diabetic retinopathy, is driving demand for these products, further supported by South Korea's aging population.

    Notably, advances in medical technology and the integration of artificial intelligence in ophthalmic devices are enhancing diagnostic accuracy and treatment efficacy, presenting vast opportunities for market expansion. The government has also implemented various health initiatives aimed at increasing public awareness about the importance of regular eye examinations, which complements market growth.

    Furthermore, there is a noticeable trend towards minimally invasive surgical methods, which is propelling the development and adoption of innovative devices designed for better surgical precision and quicker recovery times. The South Korea Ophthalmic Drugs and Devices Market statistics reflect an ongoing commitment to improving eye health and treatment methodologies through research and development efforts, ensuring that both drugs and devices address the evolving needs of the population effectively. As healthcare professionals continue to seek effective treatment solutions, this segment is expected to adapt and evolve, establishing a significant foundation for future innovations in the industry.

    Ophthalmic Drugs and Devices Market Treatment Insights

    The Treatment segment of the South Korea Ophthalmic Drugs and Devices Market plays a crucial role in addressing various eye-related ailments, reflecting the increasing demand for effective therapeutic solutions. Eye infections have been a prominent area of concern, with a rising prevalence due to factors such as environmental pollution and lifestyle changes, leading to a significant focus on developing targeted therapies.

    Allergic conjunctivitis remains a common issue in South Korea, driven by high pollen levels and urban pollution, highlighting the need for advanced antihistamines and anti-inflammatory treatments. The dry eyes syndrome is notably significant, with a large portion of the population experiencing symptoms primarily due to prolonged screen exposure, prompting innovation in artificial tears and moisture-retaining solutions.

    Additionally, the segment addressing red eyes and inflammation is essential for the management of ocular conditions caused by both environmental and chronic factors. The introduction of new treatments in other unspecified categories also plays a role in expanding the portfolio of options available for patients. Overall, the dynamic landscape of the Treatment segment reflects the ongoing efforts to enhance the quality of care in the South Korea Ophthalmic Drugs and Devices Market, driven by advancing Research and Development and a growing awareness of eye health among the population.

    Get more detailed insights about South Korea Ophthalmic Drugs Devices Market

    Key Players and Competitive Insights

    The South Korea Ophthalmic Drugs and Devices Market is characterized by a blend of advanced technology, significant research and development efforts, and a keen focus on patient-centric solutions. The competitive landscape is shaped by both domestic and international players, each vying for market share through innovation and strategic partnerships.

    A growing aging population, alongside an increase in eye-related conditions, is driving demand for a wide range of ophthalmic products including therapeutic agents, surgical devices, and diagnostic tools. As the market evolves, companies are tapping into cutting-edge advancements such as biologics and minimally invasive surgeries to improve patient outcomes and capture a more considerable foothold in this lucrative sector.

    Amgen has established a robust presence in the South Korea Ophthalmic Drugs and Devices Market, underscoring its commitment to enhancing eye health through its innovative product offerings. The company stands out due to its strong research foundation, which emphasizes the development of biologic drugs aimed at treating major ocular diseases.

    With a strategic focus on local partnerships and a deep understanding of regional healthcare needs, Amgen has successfully positioned itself as a leader by tailoring its therapies to better align with South Korean market demands. Furthermore, the company leverages its global expertise and technological capabilities to enhance its product effectiveness and accessibility, strengthening its footprint in this competitive landscape.

    Sun Pharmaceutical is another key player in the South Korea Ophthalmic Drugs and Devices Market, known for a diverse portfolio of ophthalmic products that address both surgical and therapeutic needs. The company's strengths lie in its innovative R&D facilities and a strong distribution network that ensures efficiency and accessibility of its products in the region.

    Sun Pharmaceutical is particularly recognized for its injectable formulations and advanced surgical solutions, which have gained traction among healthcare professionals and patients alike. Additionally, the company is actively pursuing strategic mergers and acquisitions to enhance its market presence further, boosting its capabilities to deliver cost-effective healthcare solutions tailored to the South Korean market. Through its commitment to quality and innovation, Sun Pharmaceutical continues to solidify its position as a trusted provider of ophthalmic drugs and devices in South Korea.

    Key Companies in the South Korea Ophthalmic Drugs Devices Market market include

    Industry Developments

    The South Korea Ophthalmic Drugs and Devices Market has recently experienced notable developments, with a significant focus on innovation and market growth. Companies like Alcon and Novartis are actively expanding their product lines, particularly in minimally invasive surgical devices, which have gained traction among healthcare professionals.

    Amgen and Ocular Therapeutix are also investing heavily in Research and Development for novel therapeutic solutions in treating eye conditions. In September 2023, Johnson and Johnson announced enhancements in their surgical instrument technology aimed at improving patient outcomes. Additionally, in July 2023, Merck acquired a smaller firm specializing in retinal therapies, further solidifying its presence in this competitive market.

    The current valuation of the South Korean ophthalmic sector has seen an upward trend, attributed to aging populations and increasing prevalence of eye diseases, compelling major players to increase their strategic partnerships and investments. Aerie Pharmaceuticals and Santen Pharmaceutical are also ramping up their activities in the field, responding to the growing demand for advanced eye care solutions. The solid regulatory framework in South Korea continues to foster a vibrant market environment conducive for these companies to thrive and innovate.

    Market Segmentation

    Ophthalmic Drugs and Devices Market Product Outlook

    • Drugs
    • Devices

    Ophthalmic Drugs and Devices Market Treatment Outlook

    • Eye Infections
    • Allergic Conjunctivitis
    • Dry Eyes Syndrome
    • Red Eyes
    • Inflammation
    • Others

    Report Scope

    Report Attribute/Metric Source: Details
    MARKET SIZE 2018 1.15(USD Billion)
    MARKET SIZE 2024 1.25(USD Billion)
    MARKET SIZE 2035 7.2(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR) 17.254% (2025 - 2035)
    REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR 2024
    MARKET FORECAST PERIOD 2025 - 2035
    HISTORICAL DATA 2019 - 2024
    MARKET FORECAST UNITS USD Billion
    KEY COMPANIES PROFILED Amgen, Sun Pharmaceutical, Alcon, Merck, Ocular Therapeutix, Johnson & Johnson, Glaukos, MediEye, Bausch Health, Aerie Pharmaceuticals, AbbVie, Hugel, Novartis, Santen Pharmaceutical
    SEGMENTS COVERED Product, Treatment
    KEY MARKET OPPORTUNITIES Telemedicine for eye care, Growing aging population, Increased prevalence of eye diseases, Innovation in minimally invasive procedures, Expanding reimbursement policies for eye treatments
    KEY MARKET DYNAMICS Aging population increase, Rising prevalence of eye diseases, Advanced technological innovations, Growing healthcare expenditure, Increased demand for vision correction
    COUNTRIES COVERED South Korea

    FAQs

    What is the projected market size of the South Korea Ophthalmic Drugs and Devices Market in 2024?

    The projected market size of the South Korea Ophthalmic Drugs and Devices Market is 1.25 USD Billion in 2024.

    What will be the estimated market value of the South Korea Ophthalmic Drugs and Devices Market by 2035?

    The estimated market value of the South Korea Ophthalmic Drugs and Devices Market is expected to reach 7.2 USD Billion by 2035.

    What is the expected compound annual growth rate (CAGR) for the South Korea Ophthalmic Drugs and Devices Market during the forecast period?

    The expected CAGR for the South Korea Ophthalmic Drugs and Devices Market from 2025 to 2035 is 17.254%.

    How is the South Korea Ophthalmic Drugs and Devices Market segmented by product type?

    The South Korea Ophthalmic Drugs and Devices Market is segmented into two main product types: Drugs and Devices.

    What is the market value of Ophthalmic Drugs in South Korea in 2024?

    The market value of Ophthalmic Drugs in South Korea is valued at 0.75 USD Billion in 2024.

    What is the forecasted market value of Ophthalmic Devices in South Korea by 2035?

    The forecasted market value of Ophthalmic Devices in South Korea is expected to reach 2.95 USD Billion by 2035.

    Who are the key players in the South Korea Ophthalmic Drugs and Devices Market?

    Key players in the South Korea Ophthalmic Drugs and Devices Market include Amgen, Sun Pharmaceutical, Alcon, Merck, and Johnson & Johnson.

    What growth drivers are influencing the South Korea Ophthalmic Drugs and Devices Market?

    Growth drivers for the market include increasing prevalence of eye diseases and technological advancements in ophthalmic devices.

    What significant trends are emerging in the South Korea Ophthalmic Drugs and Devices Market?

    Emerging trends in the market include the development of innovative drug delivery systems and personalized medicine for ocular conditions.

    How does the South Korea Ophthalmic Drugs and Devices Market compare to other regions?

    The South Korea Ophthalmic Drugs and Devices Market is positioned for substantial growth, making it a competitive region compared to others in the Asia-Pacific.

    Download Free Sample

    Kindly complete the form below to receive a free sample of this Report

    Case Study
    Chemicals and Materials